German multinational Bayer AG has acquired an 11.9% stake in Bayer CropScience Ltd for ₹2,207 crore through a block deal, according to data available on the National Stock Exchange (NSE). Following the transaction, shares of Bayer CropScience slipped nearly 1% to trade at ₹4,128 apiece on the NSE on Thursday.
Transaction Details
- Bayer AG, a promoter entity, purchased 53,54,030 shares, representing a 11.91% stake in the agrochemical company.
- The transactions were executed on Wednesday at an average price of ₹4,122.30 apiece, taking the deal size to ₹2,207.09 crore.
- Bayer CropScience Aktiengesellschaft (AG), another promoter, sold an equal number of shares and exited the firm.
- Following the acquisition, Bayer AG's stake in Bayer CropScience increased to 20.34% from 8.43%.
- The transaction was an inter-promoter transfer and did not alter the overall promoter shareholding in the company.
Financial Performance
Bayer CropScience posted a 13% increase in net profit to ₹162.1 crore for the quarter ended March 2026, compared with ₹143.3 crore in the corresponding period a year ago. Revenue from operations for the quarter rose 5% to ₹1,100 crore from ₹1,046 crore.
For the full financial year 2025-26, the company reported a 21% growth in net profit to ₹689.2 crore, while revenue increased to ₹5,675 crore from ₹5,473 crore in the previous fiscal.
| Metric | Q4 FY26 | Q4 FY25 | Change | FY26 | FY25 | Change |
|---|---|---|---|---|---|---|
| Net Profit (₹ cr) | 162.1 | 143.3 | +13% | 689.2 | — | +21% |
| Revenue (₹ cr) | 1,100 | 1,046 | +5% | 5,675 | 5,473 | +3.7% |
Strategic Implications for Corporate Finance
For CFOs and treasury professionals, this inter-promoter stake consolidation by Bayer AG signals continued commitment to the Indian agrochemical subsidiary. The block deal pricing at ₹4,122.30 per share and the subsequent marginal price decline to ₹4,128 provide a market reference point for valuation in the sector.
The company's financial performance — 21% annual net profit growth on a 3.7% revenue increase — indicates margin expansion, a positive signal for trade finance assessments of creditworthiness. The transaction does not affect the company's capital structure or debt profile, as it is an intra-group transfer with no change in total promoter holding.
For investors and trade finance professionals, the healthy profit growth and stable revenue base support the company's credit profile. The block deal also provides liquidity depth, with over 53 lakh shares changing hands at a substantial premium to the previous close, before the slight 1% slip. Bayer AG is a Germany-based global life sciences company with operations spanning pharmaceuticals, consumer health and crop science. The increased stake may precede further strategic alignment within the group, though no further details were provided.
Sources:
